Polycythemia Vera News and Research

RSS
Celgene announces data from REVLIMID Phase III study on high-risk asymptomatic smoldering MM

Celgene announces data from REVLIMID Phase III study on high-risk asymptomatic smoldering MM

S*BIO announces results from pacritinib Phase 2 study on myelofibrosis

S*BIO announces results from pacritinib Phase 2 study on myelofibrosis

Incyte receives FDA approval for Jakafi to treat intermediate or high-risk MF

Incyte receives FDA approval for Jakafi to treat intermediate or high-risk MF

Lilly presents results of JAK2, Hedgehog inhibitor preclinical cancer studies at 102nd AACR

Lilly presents results of JAK2, Hedgehog inhibitor preclinical cancer studies at 102nd AACR

Incyte’s ruxolitinib COMFORT-II Phase III trial in MF meets primary endpoint

Incyte’s ruxolitinib COMFORT-II Phase III trial in MF meets primary endpoint

FDA grants miRagen's MGN-4893 orphan drug designation for treatment of polycythemia vera

FDA grants miRagen's MGN-4893 orphan drug designation for treatment of polycythemia vera

Incyte announces achievement of $50 million in INCB18424 clinical trial

Incyte announces achievement of $50 million in INCB18424 clinical trial

EC grants orphan drug designation to S*BIO's SB1518 for treatment of myelofibrosis

EC grants orphan drug designation to S*BIO's SB1518 for treatment of myelofibrosis

Incyte Corporation publishes clinical trial data of INCB18424 drug for myelofibrosis treatment

Incyte Corporation publishes clinical trial data of INCB18424 drug for myelofibrosis treatment

Incyte Corporation enters SPA agreement with FDA for INCB18424 inhibitor

Incyte Corporation enters SPA agreement with FDA for INCB18424 inhibitor

Incyte second-quarter total revenues increase to $49.8 million

Incyte second-quarter total revenues increase to $49.8 million

Researchers create artificial RNA inhibitor to block excess blood cells formation

Researchers create artificial RNA inhibitor to block excess blood cells formation

Pennsylvania Department of Health announces new study on blood disorder Polycythemia vera

Pennsylvania Department of Health announces new study on blood disorder Polycythemia vera

Sanofi-aventis signs agreement to acquire TargeGen

Sanofi-aventis signs agreement to acquire TargeGen

Incyte announces 2009 financial results and key fourth-quarter accomplishments

Incyte announces 2009 financial results and key fourth-quarter accomplishments

New research may yield more effective treatment for childhood leukemia

New research may yield more effective treatment for childhood leukemia

Incyte's INCB18424 provides previously unachievable clinical benefits in myelofibrosis patients

Incyte's INCB18424 provides previously unachievable clinical benefits in myelofibrosis patients

New treatment options for leukemia and myeloproliferative disorders introduced

New treatment options for leukemia and myeloproliferative disorders introduced

S*BIO to present data on its novel oral JAK2 inhibitor at The American Society of Hematology meeting

S*BIO to present data on its novel oral JAK2 inhibitor at The American Society of Hematology meeting

New data demonstrating the strength of Novartis' hematology portfolio to be presented

New data demonstrating the strength of Novartis' hematology portfolio to be presented